We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2196:HKEXEscrit Inc. Analysis

Data as of 2026-06-03 - not real-time

HK$16.45

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Shanghai Fosun Pharma is trading below its 20‑day SMA and under the 50‑day SMA, with the RSI in oversold territory, suggesting short‑term price weakness.
However, the stock offers a low P/E relative to the industry, a solid dividend yield with a modest payout ratio, and a pipeline boost from the exclusive Alzheimer’s therapy option, which together point to a potentially attractive valuation and upside over the medium to long horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Price below short‑term moving averages
  • RSI indicating oversold conditions
  • Increasing volume but bearish MACD histogram

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Exclusive option on AR‑1001 Alzheimer’s therapy expanding growth pipeline
  • Valuation metrics (P/E, P/B) well below industry averages
  • Stable dividend yield with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Diversified healthcare portfolio across pharmaceuticals, devices, and services
  • Potential secular demand for specialty drugs and medical technologies in China
  • Attractive dividend yield and low beta indicating defensive characteristics

Key Metrics & Analysis

Financial Health

Revenue Growth6.90%
Profit Margin8.22%
P/E Ratio10.8
ROE7.04%
ROA1.53%
Debt/Equity62.09
P/B Ratio0.8
Op. Cash FlowHK$5.3B
Free Cash FlowHK$-603626560
Industry P/E27.0

Technical Analysis

TrendBearish
RSI27.6
SupportHK$16.36
ResistanceHK$19.47
MA 20HK$17.86
MA 50HK$18.93
MA 200HK$21.32
MACDBearish
VolumeIncreasing
Fear & Greed Index92.75

Valuation

Fair ValueHK$15.57
Target PriceHK$29.40
Upside/Downside78.75%
GradeFair
TypeBlend
Dividend Yield2.05%

Risk Assessment

Beta0.25
Volatility23.83%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.